scholarly journals Chemotherapeutic Properties of Phospho-Nonsteroidal Anti-Inflammatory Drugs, a New Class of Anticancer Compounds

2011 ◽  
Vol 71 (24) ◽  
pp. 7617-7627 ◽  
Author(s):  
Liqun Huang ◽  
Gerardo G. Mackenzie ◽  
Yu Sun ◽  
Nengtai Ouyang ◽  
Gang Xie ◽  
...  
Keyword(s):  
Anticancer Compounds ◽  
New Class ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Reduction of Pulmonary Inflammation by pH Modifiers

2022 ◽  
Author(s):  
Wei-ping Zeng
Keyword(s):  
Pulmonary Inflammation ◽  
Inflammatory Cells ◽  
Pathological Feature ◽  
Successful Therapy ◽  
Mucus Hypersecretion ◽  
Adverse Side Effects ◽  
New Class ◽  
Asthma Model ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Pulmonary inflammation is a common pathological feature of a variety of diseases, ofwhich successful therapy with currently available anti-inflammatory drugs is limited byresistance and adverse side effects. Using the ovalbumin-induced mouse allergic asthma model,the present study shows that treatments with pH modifiers, particularly simple acids such asacetate or hydrochloric acid, effectively depleted inflammatory cells in the lungs and blood aswell as hyperplastic lung tissue cells while preserving the structure of the blood vessels and lungparenchyma. The acid treatments also suppressed mucus hypersecretion. These resultsdemonstrated pH modifiers as a new class of broad-spectrum anti-inflammatory agents with antiproliferationand mucus suppression activities.

A new family of 2-hydroxy fatty acids as a new class of non-steroid anti-inflammatory drugs

2010 ◽  
Vol 163 ◽  
pp. S41 ◽  
Author(s):  
Daniel Horacio López ◽  
María Laura Martín ◽  
María Antonia Noguera-Salva ◽  
Silvia Terés ◽  
Gwendolyn Barceló Coblijn ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Hydroxy Fatty Acids ◽  
New Class ◽  
New Family ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Reduction of Pulmonary Inflammation by pH Modifiers

2021 ◽  
Author(s):  
Wei-ping Zeng
Keyword(s):  
Pulmonary Inflammation ◽  
Inflammatory Cells ◽  
Lung Parenchyma ◽  
Pathological Feature ◽  
Mucus Hypersecretion ◽  
Adverse Side Effects ◽  
New Class ◽  
Asthma Model ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Pulmonary inflammation is a common pathological feature of a variety of diseases, of which successful therapy with currently available anti-inflammatory drugs is limited by resistance and adverse side effects. Using the ovalbumin-induced mouse allergic asthma model, the present study shows that treatments with pH modifiers, particularly simple acids such as acetate or hydrochloric acid, effectively depleted inflammatory cells in the lungs and blood as well as hyperplastic lung tissue cells while preserving the structure of the blood vessels and lung parenchyma. The acid treatments also suppressed mucus hypersecretion. These results demonstrated pH modifiers as a new class of broad-spectrum anti-inflammatory agents with anti-proliferation and mucus suppression activities.

scholarly journals Development of NOSH-NSAIDs: a new class of anti-inflammatory pharmaceuticals for the treatment of cancer

2017 ◽  
Vol 39 (4) ◽  
pp. 24-29
Author(s):  
Khosrow Kashfi
Keyword(s):  
Human Cancer ◽  
Tumour Mass ◽  
Human Cancer Cell Lines ◽  
New Class ◽  
Cycle Arrest ◽  
Anti Cancer ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Better Than

Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-cancer (chemopreventive) properties; however, side effects preclude their long-term use. NOSH-NSAIDs, designed as safer alternatives, are novel hybrid chimaeras that release nitric oxide (NO) and hydrogen sulfide (H2S). NOSH-NSAIDs are gastrointestinally safe yet retain all the pharmacological properties of their native NSAID. NOSHNSAIDs are orders of magnitude more potent than their conventional counterparts in inhibiting the growth of various human cancer cell lines of different tissue origins, adenomatous, epithelial and lymphocytic. This growth inhibition is a result of a reduction in cell proliferation and cell cycle arrest, leading to increased apoptosis. In xenograft mouse models of cancer, NOSH-aspirin was better than normal aspirin as a chemopreventive agent; it dose-dependently inhibited tumour growth and tumour mass. NOSH-naproxen was significantly more efficacious than normal naproxen in reducing the growth of established tumours.

scholarly journals A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?

2017 ◽  
Vol 2017 ◽  
pp. 1-19 ◽  
Author(s):  
Vasiliki D. Papakonstantinou ◽  
Nefeli Lagopati ◽  
Effie C. Tsilibary ◽  
Constantinos A. Demopoulos ◽  
Athanassios I. Philippopoulos
Keyword(s):  
Organic Compounds ◽  
Platelet Activating Factor ◽  
Inhibitory Effect ◽  
Anticancer Properties ◽  
New Class ◽  
Structure Activity ◽  
Rabbit Platelets ◽  
First Results ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

In this minireview, we refer to recent results as far as the Platelet Activating Factor (PAF) inhibitors are concerned. At first, results of organic compounds (natural and synthetic ones and specific and nonspecific) as inhibitors of PAF are reported. Emphasis is given on recent results about a new class of the so-called metal-based inhibitors of PAF. A small library of 30 metal complexes has been thus created; their anti-inflammatory activity has been further evaluated owing to their inhibitory effect against PAF in washed rabbit platelets (WRPs). In addition, emphasis has also been placed on the identification of preliminarystructure-activityrelationships for the different classes of metal-based inhibitors.

Polyphenols from Cymbopogon citratus inhibit iNOS expression and NO production – a promising source of new anti-inflammatory drugs

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
V Francisco ◽  
A Figueirinha ◽  
B Neves ◽  
C Garcia-Rodriguez ◽  
M Lopes ◽  
...  
Keyword(s):  
Inos Expression ◽  
No Production ◽  
Cymbopogon Citratus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Promising Source
Sign in / Sign up

Export Citation Format

Share Document